News

EPAM Expands Financial Services with First Derivative Buyout

EPAM Expands Financial Services with First Derivative Buyout

EPAM Systems Enhances Capabilities with First Derivative Acquisition

EPAM Systems, Inc. (NYSE: EPAM), renowned for its digital transformation services, has completed a notable strategic acquisition of First Derivative. This acquisition significantly bolsters EPAM's capabilities in delivering comprehensive financial services solutions across multiple continents, including North America, Europe, and APAC.

First Derivative, headquartered in Northern Ireland, is a prominent player in managed services and consulting specifically dedicated to the capital markets sector. With over 1,800 skilled professionals globally, the firm excels in deploying innovative technology solutions to help clients tackle their most pressing technology challenges. These include advanced application development, modernization efforts, real-time data analytics, and automated processes incorporating machine learning and AI.

Balazs Fejes, President of Global Business and Chief Revenue Officer at EPAM, expressed excitement about the acquisition. He remarked, "We are eager to integrate First Derivative's exceptional team and established client base into EPAM. This synergy will combine our extensive capabilities in AI, digital solutions, and cloud technologies with First Derivative's specialized knowledge in the financial services sector. Together, we envision tremendous opportunities to enhance our offerings in regulated industries by leveraging their expertise in specialized software solutions for a wider audience."

Leveraging Expertise for Enhanced Client Services

Through this acquisition, EPAM plans to utilize First Derivative's deep industry experience to provide tailored AI-enabled capabilities across banking, capital markets, and other regulated sectors. The focus is to empower clients with innovative tools designed to deliver operational insights while adeptly managing the complexities of modern financial landscapes.

David Collins, the CEO of First Derivative, expressed his enthusiasm as well: "Joining forces with EPAM is a commendable step forward, as both firms share a commitment to driving technological innovation. Our collaboration is set to enhance the financial services landscape by delivering smarter solutions that foster operational efficiency and mitigate risks, especially in a world increasingly reliant on data-driven insights."

Details of the Strategic Acquisition

Key advisory roles were played by Stone Key Partners LLC, serving as the exclusive financial advisor, and Faegre Drinker, acting as the legal advisor for EPAM during this transaction. The acquisition successfully navigated the usual closing conditions necessary for completion, including receiving required regulatory approvals.

Exploring Financial Services Growth

This strategic acquisition marks a pivotal moment for EPAM as it seeks to amplify its financial services capabilities. The integration of First Derivative will undoubtedly allow EPAM to further enhance the solutions it offers in an ever-evolving market landscape. This will not only strengthen their service delivery but also create a robust platform for addressing the dynamic needs of their clients in the financial sectors.

About EPAM Systems, Inc.

Founded in 1993, EPAM Systems, Inc. (NYSE: EPAM) has established itself as a leader in digital engineering, cloud-based solutions, and AI transformation services. They cater to a variety of clients, ranging from large enterprises to emerging startups, helping them navigate the complexities of technological advancements. EPAM’s commitment to delivering integrated strategies ensures that clients gain maximum value from their innovative initiatives and digital investments.

EPAM is recognized not only for its expertise in technology but also for its strong emphasis on enhancing people's lives through improved solutions. With a presence across six continents, their multidisciplinary teams are committed to making tangible impacts in clients’ operations and fostering competitive advantages across various industries.

Frequently Asked Questions

What was the purpose of EPAM's acquisition of First Derivative?

The acquisition aims to enhance EPAM's financial services by adding First Derivative's expertise in managed services and consulting for the capital markets industry.

How many employees does First Derivative have?

First Derivative has over 1,800 employees worldwide.

What technologies does First Derivative specialize in?

First Derivative specializes in application development, modernization, real-time data platforms, robotic process automation, machine learning, and artificial intelligence.

Who is Balazs Fejes?

Balazs Fejes is the President of Global Business and Chief Revenue Officer at EPAM Systems, guiding the company's growth and strategy in digital transformation.

What are the expected benefits of this acquisition for EPAM's clients?

Clients can expect enhanced operational insights, improved risk management, and innovative solutions tailored for regulated industries through the capabilities that First Derivative brings to EPAM.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 283

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 240

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 243

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 235

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 251

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Community in Shock After Fatal Bakersfield Shooting

Updated Category News Views 164

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 205

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Electric Vehicle Production with Smart Technology

Updated Category News Views 153

Rockwell Automation Enhances Lucid's EV Manufacturing Rockwell Automation, Inc. (NYSE: ROK), renowned for its commitment to industrial automation and digital transformation, is set to significantly enhance the electric vehicle (EV) production capabilities for Lucid. This collaboration aligns with Saudi Arabia's Vision 2030, aiming to develop a sustainable and diversified...

Continue Reading
TeraWulf Inc. Seeks Growth with Convertible Notes and Google Deal

Updated Category News Views 158

TeraWulf Stock Overview TeraWulf Inc. (NASDAQ: WULF) is observing fluctuations in its stock value amidst significant financial developments. The company's stock experienced a minor drop of 0.96%, settling at $9.29 in pre-market trading. Investors are closely monitoring the implications of recent announcements on the company's future Convertible Notes Offering Details...

Continue Reading
Kaltura's Growth Prospects and Strategic Insights Explored

Updated Category News Views 301

Kaltura got analysts buzzing back in 2024 with their second-quarter results that had the desks reeling. Adjusted EBITDA hit $1.6 million when everyone was just hoping for $0.2 million. Revenue? $44 million, up from the expected $43.1 million—these numbers showed Kaltura wasn’t just treading water; they were swimming against the tide. Kaltura's Performance Metrics: A...

Continue Reading
Nvidia's Unprecedented Market Influence in the AI Era

Updated Category News Views 139

Nvidia's Rise as a Technological Powerhouse Nvidia Corporation (NASDAQ: NVDA) has reached a new peak in its market valuation, crossing a staggering $4 trillion. Investors have welcomed the recent news regarding the resumption of sales of its advanced AI chips, boosting trust in the company's future prospects. This surge heightens interest in Nvidia, showcasing a potential...

Continue Reading
Global Oil Prices Drop Amid Trade Tensions and Demand Concerns

Updated Category News Views 392

Oil Prices Facing Declines Recent trends indicate that oil prices have been on a downward trajectory, particularly influenced by uncertainties surrounding geopolitical tensions and tariffs imposed by the U.S. However, a critical observation is that these factors intertwine to significantly affect global economic conditions and energy demand. Current Status of Oil Pricing...

Continue Reading